AbCellera is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies to address pandemics and common diseases. Co.'s full-stack, artificial intelligence-, or AI, powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. Rather than advancing its own clinical pipeline of drug candidates, Co. forges partnerships with drug developers of all sizes, from pharmaceutical to small biotechnology companies. In a collaboration with Eli Lilly and Company, Co. has applied its technology stack to co-develop LY-CoV555, a potential antibody therapy to treat and prevent COVID-19. The ABCL YTD return is shown above.
The YTD Return on the ABCL YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ABCL YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ABCL YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|